The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.
The renewed interest in strategies to combat infectious agents with epidemic potential has led to a re-examination of vaccination protocols against smallpox. To help define which antigens elicit a human antibody response, we have targeted proteins known or predicted to be presented on the surface of the intracellular mature virion (IMV) or the extracellular enveloped virion (EEV). The predicted ectodomains were expressed in a mammalian in vitro coupled transcription/translation reaction using tRNA(lys) precharged with lysine-epsilon-biotin followed by solid phase immobilization on 384-well neutravidin-coated plates. The generated array is highly specific and sensitive in a micro-ELISA format. By comparison of binding of vaccinia-immune sera to the reticulocyte lysate-produced proteins and to secreted post-translationally modified proteins, we demonstrate that for several proteins including the EEV proteins B5 and A33, proper recognition is dependent upon appropriate folding, with little dependence upon glycosylation per se. We further demonstrate that the humoral immune response to vaccinia among different individuals is not uniform in specificity or strength, as different IMV and EEV targets predominate within the group of immunogenic proteins. This heterogeneity likely results from the diversity of HLA Class II alleles and CD4 T helper cell epitopes stimulating B cell antibody production. Our findings have important implications both for design of new recombinant subunit vaccines as well as for methods of assaying the human antibody response utilizing recombinant proteins produced in vitro.
Duke-Cohan
Jonathan S
JS
Laboratory of Immunobiology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jonathan_duke-cohan@dfci.harvard.edu
Wollenick
Kristin
K
Witten
Elizabeth A
EA
Seaman
Michael S
MS
Baden
Lindsey R
LR
Dolin
Raphael
R
Reinherz
Ellis L
EL
D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000276:immunology*; D014644:Genetic Variation; D006801:Humans; D009500:Neutralization Tests; D040081:Protein Array Analysis; D012900:Smallpox Vaccine / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*; D015678:Viral Structural Proteins / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral; D012900:Smallpox Vaccine; D015678:Viral Structural Proteins